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Transmissible Spongiform Encephalopathies (TSEs) are a group of neurodegenerative 
diseases that affect humans and animals alike. TSEs are caused by the accumulation of 
a disease producing isoform referred to as PrPSc that results from the misfolding of the 
normal cellular prion protein PrPC. The pathological outcomes of TSEs include amyloid 
plaque build-up and spongiform degeneration in the brain of infected hosts. Clinical 
signs of prion disease can vary between TSEs, but often include neurologic impairment 
that is subtle in onset and tends to progress slowly. Prion diseases are relatively 
recently discovered and have sparked much controversy due to the scientific findings 
that directly challenge some of the most well established scientific dogmas. Among 
these is that the infectious agent responsible for the transmission of TSEs is 
proteinacious in nature and devoid of the nucleic acids present in pathogens like viruses 
and bacteria. As a result of this hypothesis, both PrPC and PrPSc share the same amino 
acid sequence in the host. Therefore, central to our understanding of the prion 
hypothesis is to recognize the structural differences between PrPC and PrPSc. PrPC has 
been proven to include three α-helices and two, short β-pleated sheets whereas PrPSc 
consists of high β-sheet content, aggregates in the presence of detergents, and is 
resistant to protease treatment. These characteristics of PrPSc have inhibited 
researchers to successfully examine the abnormal isoform in high-resolution structural 




Since then, several groups have created monoclonal antibodies (mAbs) that 
differentiate between infectious prion protein (PrP) aggregates. Two such mAbs, PRC5 
and PRC7 were the first mAbs discovered in which the involvement of individual 
residues in functional, discontinuous, and conformationaly dependent epitopes was 
studied. Of these antibodies, PRC7, is dependent on N-linked glycosylation at mono-1 
of the prion protein and specifically binds to the infected isoform of PrP. Therefore, we 
hypothesized that an underglycosylated form of PrP is preferentially generated during 
prion replication in the infected host. In this body of work, we have systemically ablated 
mono-1, one of the two N-linked glycan attachment sites on the murine prion protein to 
address the role of underglycosylation in prion propagation at N180 and at S/T182 of 
the consensus sequence by mutating N or S/T to each of the other 19 amino acids 
individually. Here we present novel evidence showing the effects of underglycosylation 
in prion propagation of prion isolates RML, 22L, 139A, and mCWD. These preliminary 
data demonstrate the importance of post-translational differences between PrPC and 
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Prion Diseases       
Introduction to Transmissible Spongiform Encephalopathies 
Prion diseases encompass a variety of unique ailments that affect animals and humans 
alike. These diseases are collectively referred to as Transmissible Spongiform 
Encephalopathies. The hallmarks of TSEs include a combination of spongiform change, 
astrocytic inflammation, neuronal loss, as well as amyloid plaques that build up and 
cause impaired brain function that worsen overtime. 
 
History of Animal TSEs 
Scrapie is the prototypic prion species causing disease in both sheep and goats. 
Because scrapie has been recognized for over 200 years in Europe, it has often been 
referred as the main reference for prion diseases, especially as it has become a 
worldwide epidemic (McGowan and Scott, 1922).  
 
More recently recognized animal prion diseases have been described in both captive 
and wild animals.  These include transmissible mink encephalopathy (TME), feline 
spongiform encephalopathy (FSE), chronic wasting disease (CWD), and bovine 
spongiform encephalopathy (BSE). In all of these cases, infected animals exhibit some 
combination of clinical signs that are usually insidious in onset and tend to progress 
slowly. In these TSEs, signs tend to be neurologic in nature and once they appear, 




TME has been described as a rare, sporadic TSE that affects ranch-raised mink that are 
bred for their pelts. The only constant factor in the spread of TME is mink feed. Clinical 
signs of this disease differ from other animal TSEs in that the mink initially become 
hyperactive and aggressive before exhibiting other clinical signs of prion disease 
(Hadlow, 1999; Harstough and Burger, 1965; Marsh et. al., 1991; Marsh and Hadlow, 
1992; and McKenzie et. al., 1996). FSE, a TSE of domestic and captive wild cats was 
originally identified in 1990 (Gruffydd-Jones et. al., 1992; Wyatt et. al., 1991). Naturally 
occurring CWD is a TSE of deer and elk highly prevalent in North America and parts of 
Canada and uniquely affects both free-ranging and captive cervid populations (Spraker 
et. al., 1997; Williams and Young, 1980). More recently, CWD has been detected in 
moose and reindeer in Europe (Benestad et. al., 2016). Finally, BSE, a TSE of cattle, 
rapidly developed into an endemic in the United Kingdom (UK) as a result of recycling 
contaminated feed in industry farms (Anderson et. al., 1996; Collinge, 2001; Hadlow, 
1999; Wells et. al., 1987; Wilesmith et. al., 1988). 
 
History of Human TSEs 
Human prion diseases are classified into several groups that include Creutzfeldt-Jakob 
disease (CJD), Gerstmann-Straussler syndrome (GSS), and kuru. These human TSEs 
are organized further into three etiological categories: sporadic, acquired, and inherited 
(Collinge, 2001; Soto, 2007).  
 
Acquired prion diseases include iatrogenic CJD and kuru, which arise through the 




Sporadic CJD is rapidly progressive disease that arises randomly and occurs all over 
the world. It also accounts for the majority of all recognized human prion diseases, 
occurring in a large percentage of all reported human cases (Palmer et. al., 1991). 
Lastly, inherited prion diseases like GSS, familial CJD, and fatal familial insomnia (FFI), 
are associated with coding mutations in the prion protein gene (Collinge, 1997).  
 
There is also evidence of another segmentation of human prion disease called variant 
CJD (vCJD) in the UK. Experimental data shows that vCJD is cause by the same prion 
strain that causes BSE in cattle leading to the concern that dietary exposure to BSE 
prions may lead to an epidemic of vCJD in the human population in the UK (Collinge, 
1999; Cousens et. al., 1997; Ghani et. al., 1998; Hill et. al., 1997).  
 
Collectively, concerns of zoonotic potential combined with iatrogenic transmission have 
intensified efforts for investigators to better understand prion propagation at the 
molecular level. This is necessary to further develop new and effective therapeutic and 
preventative treatments for prion diseases. 
 
Transmissibility      
In 1936, scrapie was shown to be transmissible by inoculation into uninfected sheep 
and goats (Cuille and Chelle, 1936). In these studies, researchers observed extended 
incubation times to the onset of observable disease-like symptoms. Because of this 




Sigurdsson coined the term slow-acting infection to represent the phenomenon 
(Sigurdsson, 1954).  
 
Around that same time, there was growing interest in an epidemic occurring in the Fore 
linguistic group of Eastern Highlands of Papa New Guinea because of a 
neurodegenerative disease called kuru, the prominent clinical aspect being progression 
into ataxia. Eventually, several groups of researchers concluded that kuru was being 
transmitted during cannibalistic feasts. And in 1959, Hadlow brought attention to kuru by 
citing the remarkable similarities it shares with scrapie. He ultimately suggested that the 
two diseases were parallel in their epizootiological, etiological, clinical, and pathological 
features indicating that these diseases could also be transmissible (Hadlow, 1959).  
 
The next major turning point in the field came in 1966 when Gajdusek successfully 
transmitted kuru into chimpanzees by inoculation into the brain. Gibbs also showed that 
the same transmission was true of CJD in 1968, and later Masters in 1981 with GSS 
(Gajdusek et. al., 1966; Gibbs et. al., 1968; Masters et. al., 1981). Collectively, these 
studies eventually led to the concept of “transmissible dementias” which encompasses 
a variety of neurodegenerative conditions (Collinge, 2001). 
 
The Prion Protein    
Protein Only Hypothesis 
Unlike other infectious agents, the infective agent of prion disease has proven to be 




that the infective agent was made of a nucleic acid genome because 1. the pathogen 
behaved like a virus and 2. “strains” or distinct isolates of the pathogen exhibited 
different biological properties such as incubation times and patterns of spongiosis in the 
central nervous system (CNS) (Bruce and Dickson, 1987; Dickson et. al., 1968; Dickson 
et. al, 1984). However, the initial assumption that the causative agent was a slow-acting 
virus was disputed and attempts to modify, identify, or clone nucleic acids specific to 
PrPSc have failed to generate polynucleotides of significance (Kellings et. al, 1992; 
Meyer et. al., 1991; Oesch et. al. 1988; Prusiner, 1991). 
 
Additional studies supporting the theory that PrPSc is devoid of nucleic acids emerged 
and several groups demonstrated that the agent in question was highly resilient to harsh 
treatments that are known to inactivate nucleic acids. In scrapie for example, 
researchers were unable to inactivate the infectious agent through many physical and 
chemical treatments such as boiling, freezing and thawing, formalin treatment, 
treatment with chloroform, and ultraviolet radiation (Alper, 1966; Alper et. al., 1966; 
Alper et. al., 1967; Pattison and Millson, 1961a; Pattison and Millson, 1961b; Pattison, 
1965). In 1967 Griffith took this further and suggested that the transmissible agent was 
a protein (Griffith, 1967). 
 
Despite this evidence, there was still speculation regarding this novel idea, in 1982, 
Bolton and colleagues were able to help solidify this theory when they successfully 
isolated a protease resistant sialoglycoprotein through proteinase K (PK) treatment of 




defined by Prusiner as “small proteinaceous infectious particles that resist inactivation 
by procedures which modify nucleic acids” (Prusiner, 1982).  
 
Prion Protein Isoforms  
All of the four levels of protein structure (primary, secondary, tertiary, and quaternary), 
in addition to the environment, help to stabilize the folded, native conformation of a 
protein. Therefore, a protein is only functional when in its proper conformation and 
proper three-dimensional form. An inactive protein, with some exceptions, occurs when 
it is improperly folded or denatured often leading to its degradation. 
 
In prion disease, the cellular form of the protein is converted into a new, β-sheet rich 
conformation that has an unknown tertiary structure. This is the conformation that 
causes disease. Therefore, all prion proteins exist in at least two distinct isoforms: the 
normal, cellular prion protein, PrPC and the disease causing isoform referred to as 
scrapie or PrPSc. Moreover, a large body of evidence suggests that prion disease is 
mediated by the abnormal isoform, PrPSc (Prusiner, 1991).  
 
Prion Protein Functions 
While PrPSc is infection specific, PrPC has some normal cellular functions. PrPC is highly 
conserved in most mammals and is found in most adult tissues (Ford et. al., 2002). 
However, PrPC is most prominently expressed in the CNS in synaptic membranes and 
within cells of the immune system as a glycosylphosphatidylinositol (GPI) anchored cell 




thought to include a role in oxidative stress, copper metabolism, synaptic structure, 
function and maintenance, cell adhesion, and trans-membrane signaling processes 
(Westergard et. al., 2007). However, the exact functions of PrPC within these areas 
have yet to be clearly defined. 
 
Conformational Properties of PrPC and PrPSc 
The two best approaches to analyze the atomic structure of proteins include nuclear 
magnetic resonance (NMR) and x-ray crystallography. Both approaches achieve high-
resolution analysis of protein structure. However, NMR determines the structure of the 
protein in solution, often showing regions that are dynamic and unresolved, whereas x-
ray crystallography looks at the structure in a static crystal form. 
 
The conformation of PrPC was first determined through NMR measurements made on 
recombinant mouse protein (Reik et. al., 1996). Since then, NMR structures have been 
determined for additional strains of the prion protein and have shown to consist 
essentially of the same conformation (Hosszu et. al., 1999; James et. al., 1997). Despite 
the efforts by several groups, determining the three-dimensional structure of PrPC 
through x-ray crystallographic methods has not been successful. Furthermore, the 
insoluble properties of PrPSc have prevented successful determination of its structure by 
either x-ray crystallography or NMR methods. Therefore, our knowledge of PrPSc 






Cellular Biology of PrPC and PrPSc 
In the first step of the secretory pathway, a new protein is translocated into the 
endoplasmic reticulum (ER) only after it has been fully translated in the nucleus. This 
process is called post-translational translation. Human PrP encodes a ~253 amino acid 
translational product that is moved into the ER. The first 22 amino acids of PrP code for 
a signal peptide and cause the mRNA/ribosome complex to move into the ER mid-
translation. This process is referred to as co-translational translocation. These 22 amino 
acids are removed by signal peptidase from the N-terminus and PrP continues to be 
translated directly once it is in the ER. This occurs because a signal recognition particle 
(SRP) binds to and prevents the ribosome form continuing translation. Translation only 
continues when the ribosome/SRP complex encounters a SRP receptor and each bind 
to one guanosine triphosphate (GTP) molecule on the ER membrane. Once attached, 
translation continues pushing the signal peptide, and eventually the whole molecule of 
PrP into the lumen of the ER. Then, both the SRP and its receptor both hydrolyze their 
GTP and are released and the protein is free to start folding in the lumen. While the 
protein is still being translated, oligosaccharyl transferase (OST), adds glycosyl groups 
to asparagine residues in the nascent protein as a part of the translocon complex. PrP 
has 0, 1 or 2 possible sites on N-glycan consensus sequences, NXS and NXT (Harris, 
2003). 
 
The C-terminus of PrP is a 23 amino acid sequence that signals for the addition of a 
GPI anchor (Stahl et. al., 1987). In this process called glypiation, 23 amino acids are 




then embeds into the membrane and anchors PrP to the ER. After cleavage of the 
signal peptide and the addition of the GPI anchor, human PrP becomes ~208 amino 
acids in length. Collectively, these processes produce a ~17kDa C-terminal fragment 
called C1 that is inserted into the plasma membrane of the cell and a ~9kDa 
unstructured and soluble N-terminal counterpart referred to as N1 that is released into 
the extracellular space (Chen et. al., 1995). 
 
From the ER, GPI-linked PrP travels anterograde through the secretory pathway. It is 
transported in vesicles that bud off of the ER bound for the golgi apparatus for further 
modification and acquire a disulfide bond between its two cysteine residues C180 and 
C214 and also undergoes several modifications to its N-linked glycan chains. The golgi 
apparatus consists of a set of stacked sub-compartments called cinsternae that have 
different properties. These sub-compartments are celled cis, medial, and trans-golgi 
network and the modifications of proteins have to happen in a particular order within 
them. When proteins have finally completed maturation, they do one of three things. 
They either bud off in a vesicle and are exocytosed and fused with the cell membrane, 
get moved into secretory vesicles until needed, or they are placed into lysosomes if they 
are not correctly folded. Normally, PrP gets GPI-linked and delivered to the cell surface 
through an exocytic vesicle. Once there, it remains GPI-anchored to the surface of the 
cell membrane. Moreover, it has been shown that the majority of PrP on the cell surface 
is found within cholesterol and sphingolipid enriched domains (Hnasko et. al., 2010). 
However, there is evidence that PrP can exist in three membrane topologies including 




However, in pathological conditions, PrPC undergoes an additional upstream cleavage 
of ~66 N-terminal amino acids (7kDa N-terminal peptide) and the persistence of a 
protease resistant core (C2) referred to as PrP 27-30 (Chen et. al., 1995). 
 
Structural Features of PrPC 
The resulting, mature PrPC isoform consists of two distinct parts. First, the unstructured 
N-terminal region of the protein contains a segment that includes five repeats of an 
eight amino acid sequence called the octapeptide repeat region and includes one 
binding site for copper ions thought to play a role in oxidative stress (Viles et. al., 1999). 
Studies on post-translational modifications show that PrP undergoes glycan addition at 
two asparagine (N)-linked glycosylation sites which occur on murine (mo) PrP at 
residues 180 and 196 (Bolton et. al., 1985; Oesch et. al., 1985). 
 
Second, the C-terminus aspect of PrP at amino acids 121-231 encompassing murine 
PrP, is structured as it is folded into three α-helices and two, short β-pleated sheets. 
(Fig. 2). These are stabilized by a single, di-sulfide bond that links helices two and three 
(Reik et. al., 1996). In contrast to PrPC, PrPSc has been shown by Fourier transform 
infrared spectroscopic methods to contain high β-sheet content but is indistinguishable 
from PrPC in terms of sequence (Pan et. al., 1993; Stahl et. al., 1993).  
 
Additional structural studies have shown that PrPC is monomeric, sensitive to protease 
treatment, and is soluble in detergents (Wildegger et. al., 1999). In contrast, PrPSc is 




amyloid rods (Barry et. al., 1985; Meyer et. al., 1986). Treatment of PrPSc with 
proteinase K results in cleavage and the persistence of a protease resistant core PrP 
27-30. 
 
Prion Propagation and Recruitment 
The molecular events that occur during infection which lead to the conversion of PrPC to 
the diseased isotype, PrPSc, are still poorly understood. It is known that PrPSc is derived 
from PrPC through post-translational modifications (Borchelt et. al., 1990; Caughey and 
Raymond, 1991). Though no differences between the amino acid sequence of PrPC and 
PrPSc have been found, it was proposed that PrPSc acts as a template to promote the 
conversion of PrPC to PrPSc through either a post-translational or conformational 
modification (Stahl et. al., 1993). Additional PrPC molecules can then be recruited and 
lead to further conversion; which is dependent on the overall PrPC concentration, 
resulting in the etiology of prion disease (Fig. 1) (Halliday et. al., 2014; Prusiner et. al., 








Figure 1. Schematic of Prion Conversion Native PrP
C
 (blue) is converted into PrP
Sc
 (black) through 










N-Linked Glycosylation in PrP 
Detecting TSEs does not come without difficulty as the most reliable confirmations of 
disease are performed post-mortem. Screening animals and humans for PrPSc is not 
possible as PrPSc is derived straight from the host and is not recognized by self as 
foreign. As a result, there is no adaptive immune response mounted during infection to 
activate T and B cells. This makes attempts to isolate PrP monoclonal antibodies 
(mAbs) challenging. Additionally, abnormal accumulation of PrPSc is concentrated in the 
brain and is difficult to detect in other bodily fluids and tissues (Kubler et. al., 2003).  
 
Therefore, the gold standards for post-mortem detection of PrPSc include: a) 
immunohistochemistry (IHC), b) immunoblotting (WB), as well as c) bioassay of infected 
brain material into a susceptible host to demonstrate the transmission of infectious 
particles (Hadlow, 1999; Hnasko et. al., 2010; MacGregor, 2001; Pawel, 2004). 
 
Consequently, to develop innovative diagnostics and treatments for prion diseases, it is 
important to gain a better understanding of the molecular mechanisms by which prions 
replicate and cause disease. It is therefore essential to grasp post-translational 
differences, such as glycosylation, between PrPC and PrPSc, and the role they play in 




Historically, the role of N-linked glycosylation and its role in prion propagation has been 
a subject involving much controversy (Cancellotti et. al., 2007). N-linked glycosylation 
involves an enzymatic transfer of a lipid-linked carbohydrate onto the acceptor 
asparagine of the consecutive amino acid sequence that serves as the N-glycan 
recognition sequence: asparagine (N)-X-serine (S)/threonine(T), where X is any amino 
acid other than proline (P). PrP has two highly conserved sites for N-glycan attachment 
at murine residues 180 and 196. Occupancy at these two sites yields four different 
glycotypes: fully-glycosylated PrP (di-glycosylated), as well as three under-glycosylated 
forms including mono-glycosylated at 180 (mono-1), mono-glycosylated at 196 (mono-
2), and completely aglycosylated with no glycan attachment at either site. N-linked 
glycosylation is one of the most common post-translational modifications of extracellular 
membrane proteins and results in great functional diversity of proteins including protein 
folding, stability, and aggregation (Hanson et. al., 2009; Mitra et. al., 2006). 
 
Mapping Functional Epitopes 
The involvement of specific amino acid residues in conformational epitopes and their 
effects on PrP during infection have only just begun to be defined. There is an 
advantage to understanding the involvement of specific amino acid residues in 
discontinuous, conformational-dependent PrP epitopes as it could provide a means to 
better understanding PrP biochemically both in structure and interactions and can pave 





Earlier studies by Kang and colleagues (Kang et. al., 2012) aimed to define the 
involvement of specific amino acid residues in discontinuous, conformation dependent 
PrP epitopes and their role in prion propagation. These studies used shuffled genes 
expressing novel PrP epitopes to determine the reactivities of the resulting mAbs 
against a large panel of PrP primary structures and polymorphic variants. The goal was 
to map out and confirm by mutational analysis the involvement of specific residues on 
epitope binding and PrPC to PrPSc conversion (Fig. 2).  
 
Results show that binding of one monoclonal antibody in particular, PRC7, is sterically 
prevented by N-glycan occupancy at residue N196 on the murine PrP (mono-2) and as 
a result, recognizes only the mono-1 and aglycosylated species of PrP (Kang et. al., 
2012). Through additional studies it was shown that PRC7 recognizes a discontinuous 
epitope on murine PrP that includes Y154, Q185, and F197 in the globular region of the 
protein and requires proximity in the folding of the tertiary structure of PrP for 
recognition. Furthermore, these studies showed that PRC7 reactivity of PrP increases 
during infection and thus mono-1 or aglycosylated PrP could be specific to PrPSc.  
 
Other mAbs of significance to mention include PRC5 and D13. The former recognizes a 
discontinuous epitope on murine PrP including A132 and N158 in the globular region 
and like PRC7, also requires proximity for recognition in the tertiary structure of the 
PrPC. Unlike PRC7, immunoreactivity to this mAb does not increase during infection.  
Because of its location and properties, PRC5 acts very similar to the widely studied 6H4 




(Kang et. al., 2012; Korth et. al., 1997). Finally, mAb D13 consists of a continuous, 
linear epitope upstream of the globular region of murine PrP at 94-105 and does not 
depend on the tertiary structure of the protein for recognition and is not specific to 




These data suggest that conversion of PrPC to PrPSc depends largely on its state of 
glycosylation. Additionally, these data also provide a means of distinguishing PrPC from 
PrPSc immunologically, without reliance on protease treatment and provide an option for 
use in WB, IHC, and other assays in the future. 
 
Systemic Mutation of N-Glycan Attachments on Murine PrP 
Preliminary Data – Mono-2 Substitutions 
In preliminary, unpublished studies by Kang and colleagues, an innovative molecular 
genetic method was used as a way to remove N-linked glycosylation at residue 196 and 
Figure 2. Mapping of mAbs Generated Murine PrP shown with mAbs of significance in this body of 




the downstream T at 198 on murine PrP in order to systematically study the role of 
underglycosylation in prion propagation. These studies mutated the N at glycan residue 
196 and the T at site 198 to each of the remaining 19 amino acids individually. 
Thereafter, these constructs were stably transfected into Rabbit Kidney Epithelial cells 
(RK13), which do not endogenously express PrP (Vilette et. al., 2001). 
 
Through immunoblotting and probing with PRC5 and PRC7, results showed that these 
mutations did not affect the ability of the globular domain to attain the appropriate 
tertiary structure required for the recognition of PrPC (Fig. 3). Additionally, as expected, 
detection with PRC5 showed that all mutations prevented the formation of di-
glycosylated PrP by preventing glycosylation at 196. The resulting immunoreactive 
bands included a ~27kDa unglycosylated full length PrP and its ~33kDa 
monoglycosylated counterpart, mono-1; as well as a ~17kDa C1 fragment and its ~22 
kDa monoglycosylated counterpart (Fig. 3). The two exceptions to these results include 
substitutions N and S made at 198 in which the fully di-glycosylated form of PrP was 
also produced. This can be easily explained by the fact that the third residue required 
for N-glycosylation attachment can be either an S or a T. Moreover, because residue 
200 is a T, the T198N mutation creates an additional cryptic N-glycan attachment site 








After confirmation of PrPC expression of these constructs, these mutant cells were 
subsequently infected with prion isolates RML, 22L, 139A, and mCWD. Following four-
weeks of infection, cells were counted and plated onto ELISpot plates, immunodetected 
with 6H4; a widely used, commercially available mAb (Thermo Fisher Scientific, Cat. 
#7500997) with a linear epitope located at amino acids 144-152 on PrP (Korth et. al., 
1997; McCutcheon et. al., 2014), and spots from single cells were counted. Outcomes 
show that substitutions at both N196 and T198 exhibited variability between each of the 
prion isolates with the exception of lysine (K) at 196, in which prion propagation was 
detected in all four (Fig. 4). Because of this interesting result, N196K will be the focus 
for future studies. 
Figure 3. Mono-2 Glycan Site Mutation Western Blots Probed with PRC5 and PRC7 N196 and 
T198 site mutations in mo PrP are shown. Blots were probed with mAbs PRC5 (blue boxes) and 
PRC7 (red boxes). All samples containing glycan substitutions showed detection of all PrP glycoforms 







Even though N196K supported the conversion of PrPC to PrPSc by allowing prion 
propagation, this same mutation may not have similar effects on the second glycan 
attachment site, at residue N180 (mono-1) or its recognition sequence, S/T182. This is 
primarily because the mono-1 and mono-2 consensus sequences (NXS/T) occur in very 
different areas of the primary and secondary structures of PrPC. Mono-2 is located in 
the linker region that connects α-helices two and three while mono-1 is positioned within 
Figure 4. Scrapie Cell Assay PrP
Sc
 production in different murine prion isolates RML (blue), 22L 
(red), mCWD (magenta), and 139A (orange) for N196 (circles) and T198 (squares) site substitutions. 
Each mutant was infected and plated along with controls; cells containing the empty vector (Co), cells 
expressing WT mo PrP chronically infected with RML (first Wt), and freshly infected cells expressing 
WT mo PrP (second Wt) onto ELISpot plates 4-weeks after infection. Detection of infected cells was 
done using mAb 6H4. Prion propagation was variable between both mutation sites and isolates tested 
with the exception of the lysine (K) substitution at N196 (arrow), in which all four isolates provided 




α-helix two. Therefore, it is important to first investigate the role of these same amino 
acid substitutions at mono-1 during prion infection in order to proceed with further 
studies thereafter. 
 
The strategies started by Kang and colleagues to study each amino acid substitution at 
both mono-1 and mono-2 are continued in this body of work. These studies take a 
unique approach to studying the role of glycosylation in prion propagation by addressing 
each N-glycan attachment sequence on PrP with individual amino acid changes. This is 
essential because each of the glycan attachment sites on PrP is located in unique areas 
of the protein and may affect prion propagation differently. 
 
Introduction to this Body of Work 
In this body of work, I continued the efforts performed previously by Kang and 
colleagues by investigating the effects of amino acid mutations at the N180 glycan site 
(mono-1) on murine PrP in prion propagation. I utilized one of the gold standards, 
immunoblotting, as my readout for baseline PrPC detection as it remains a reliable, 
widely accepted molecular technique. The readout for prion propagation, known as the 
scrapie cell assay (SCA), was used following infection with several lysates. In addition, I 
also used the same laboratory-generated monoclonal antibodies as they provide a new, 
promising tool for prion detection. 
 
Overarching Hypothesis and Specific Aims  
My central hypothesis is that an underglycosylated form of PrP is preferentially 




Specific Aim 1: Investigate the relationship of individual mono-1 mutations on 
murine PrP by analyzing their effects on PrPC expression. 
Specific Aim 2: Address which substitutions at mono-1 are of significance in 
murine prion propagation using four prion isolates. 
 
Experimental Procedures 
Generation of Constructs 
PrP coding sequences with or without single mutations for each of the 19 amino acids at 
N180 or S/T182 of the murine PrP transcript variant 1 mRNA sequence (NCBI reference 
sequence, NM_011170.3) were synthesized (GeneScript, NJ) in a pIRESpuro.3 vector 
(Clonetech, Cat. #631619) with only a single restriction endonuclease recognition sites 
for each AflII and EcoRI at 5’ and 3’ respectively and ampicillin resistance (Fig. 5A,B). 
Ligations were transformed into Top10 chemically competent E. coli cells (Invitrogen, 
Cat. #C404006) according to the provided chemical transformation protocol and grown 

















Single colonies were immediately selected and inoculated into 3mL of Luria (LB) broth 
containing 100µg/mL ampicillin and expanded for 12-18hrs at 37ºC with agitation. The 
next day, glycerol stocks were made using 500µL of culture and 500µL of 50% glycerol 
and frozen at -80ºC for long-term storage.  
 
Figure 5. Generation of Mutant Constructs Sequences containing individual amino acid mutations 
at N180 and S/T182 of the N-glycan consensus sequence were designed on murine PrP. N180 
represents the mono-1 attachment site and is shown in red along with N196 site for mono-2 (A). 




Plasmid DNA was then isolated from the remaining construct cultures using the 
QIAprep Spin Miniprep Kit (Qiagen, Cat. #27104) and concentrations were measured 
using a NanoDrop 2000c Spectrophotometer (Thermo Scientific). At the same time, 
samples were checked for acceptable salt contamination (260/230) and purity (260/280) 
ratios of ~2.0 and 1.9 respectively (Thermo Fisher Scientific, 2009).  
 
Confirmation of Constructs 
To confirm that all constructs generated contained the appropriate plasmid and insert, 
restriction digests using EcoRI and AflII were set up using 1µg of plasmid DNA, 1µL of 
each restriction enzyme, 3µL of 10x Buffer (NEB), and brought up to a volume of 30µL 
with dH2O. These mixtures were then incubated at 37ºC for 1-hour, DNA fragments 
separated on a 0.8% agarose gel containing EtBr at 100V for 1-hour, and visualized by 
ultraviolet (UV) light box. Results show that two products form, one at the expected 













Additionally, 1µL of undigested DNA from all constructs were separated on a 0.8% 
agarose gel containing EtBr at 100V for 1-hour, and visualized using a UV light box to 
determine the relative ratios of naked/circle, linear, and supercoiled DNA (red boxes). 
Supercoiled is the native form of DNA found in-vivo and occurs when extra twists are 
introduced into the double helix strand. Furthermore, supercoiled DNA is the desired 
species when isolating plasmid DNA to use for stable transfections because this 
species results in greater transfection efficiency, increasing the chances of a stable 
transfection (Cherng et. al., 1999). Results confirm that each DNA species is present in 
all construct DNA samples with supercoiled DNA at an acceptable relative ratio to 








Figure 6. Digested DNA from Generated PrP Mutants DNA from N180 (A) and S/T182 (B) mutant 
cells digested with restriction enzymes EcoR1 and AflII. Results confirm two bands, one at the vector 











Following confirmation that satisfactory plasmid DNA was generated to use for 
transfections, Rabbit kidney epithelial cells (RK13) previously obtained from the 
American Type Culture Collection (ATCC, Cat. #CCL-37) were transfected in bulk with 
random insertion of plasmid (pIRESpuro.3) DNA containing murine wild-type (WT), 
altered murine PrP sequence, or empty vector to produce RKM (RKM 1-3), RK13 
mutants, and RKV cells respectively.  
 
Figure 7. Undigested DNA from Generated PrP Mutants DNA from N180 (A) and S/T182 (B) 
mutant cells. Results show the relative ratios of naked/circle, linear, and supercoiled DNA. Supercoiled 




One day prior to transfection, RK13 cells were counted and 4x105 cells/well were plated 
onto 6-well tissue culture (TC) plates in 2mL of media without antibiotics. The following 
day, transfection mixtures were prepared by mixing 2µg of plasmid DNA and 3.4µL of 
Lipofectamine 2000 (Invitrogen, Cat. #11668019) into a total of 1000µL of OptiMEM 
(Gibco, Cat. #31985070) and plated onto the cells. Following a 5-hour incubation at 
37ºC, 2mL of complete DMEM medium (HyClone, Cat. #SH30022.01) containing 
1µg/mL penicillin/100 U/mL streptomycin and 10% FBS (Peak Serum, Cat. #PS-FB1) 
was added. The next day, cells were trypsinized (HyClone, Cat. #SH30236.01) and 
transferred into 10cm2 TC dishes containing 10mL of complete DMEM and maintained 
in 37ºC with 5% CO2.  
 
Puromycin (puro) (Sigma Aldrich, Cat. #P8833) selection began 24-hours later at a 
concentration of 1µg/mL and was refreshed every 2-4 days. Death of cells lacking the 
plasmid insert began a few days post-transfection and continued through to ~1.5 weeks 
in no vector controls.  
 
Successful visualization of single colonies in all cells containing the vector (RKM, RK13 
mutants, and RKV) began around 1-week post-transfection and continued as dishes 
grew to confluency. At this time, all constructs were split into three, 10cm2 TC dishes to 
a) be frozen down in DMEM without antibiotics containing 10% DMSO for later use, b) 
harvested for protein for western blot analysis (WB), and c) maintained in complete 
DMEM with puromycin to be used for prion infections and to be later analyzed by SCA 




Western Blot Analysis 
To determine the base-line expression levels of the PrPC, cell pellets of all constructs 
were individually lysed in 200µL of cold lysis buffer (CLB) containing 50mM Tris pH 8.0, 
150 mM NaCl, 0.5% sodium deoxycholate, 0.5 igpal CA-630 and analyzed through 
western immunoblotting. 
 
Protein concentrations of cell lysates were determined by bicinchoninic acid assay 
(BCA) (Pierce, Cat. #23225). Aliquots containing 50µg of total protein were prepared for 
SDS-PAGE, and boiled for 10-minutes prior to loading. Proteins were separated on 18-
well, Criterion XT 12% acrylamide gels (Bio-Rad, Cat. #3450118) and transferred to 
polyvinylidene difluoride immobilon (PVDF)-FL membranes (EMD Millipore, Cat. 
#IPFL00010). Membranes were blocked with a 1:1 dilution of casein blocking solution 
(LI-COR, Cat. #927-40200) in 1x Tris-buffered saline with 0.1% Tween-20 (TBST) and 
probed with each of the primary mAbs of interest (PRC5, PRC7, and D13) and GAPDH 
loading control in TBST at 4ºC overnight with agitation. Membranes were washed in 
TBST for three consecutive, 10-minute intervals at room temperature with agitation 
followed by incubation for 1-hour at room temperature with the appropriate fluorescently 
tagged secondary antibody (LI-COR). Membranes were washed again and protein 









It has been accepted that lesion profiling/vacuolation scoring, electrophoretic mobility, 
incubation times, among others, are reliable methods for prion strain typing (Angers et. 
al., 2010; Bessen and Marsh, 1992; Kovacs et. al., 2013). And as such, these different 
strain dependent features can be a consequence of different tertiary structures of the 
PrPSc molecules.  
 
In this body of work, RML, 22L, 139A, and mCWD murine-adapted strains were used for 
infections. RML, 22L, and 139A are distinct, biologically cloned prion strains that 
originate from sheep scrapie (Bruce et. al., 1991), whereas mouse-adapted CWD is 
derived from chronic wasting disease prions in mule deer (Sigurdson et. al., 2006). 
 
Ethics Statement 
Mice were bred and maintained at Lab Animal Resources at CSU. This facility is 
accredited by the Association for Assessment of Lab Animal Care International in 
accordance with protocols approved by the Institutional Animal Care and Use 
Committee at CSU (IACUC Protocol #17-7266A). Mice were humanely euthanized 
using CO2 inhalation.  
 
Mice 
All mice used in this body of work were originally purchased from The Jackson 





Preparation of Brain Homogenates for Infection 
Prion infected and uninfected mice were euthanized and brain samples were harvested 
and frozen at -80ºC. Brain homogenates (BH) were prepared in 10% weight (g)/volume 
(mL) in sterile, 1x phosphate buffered saline (PBS). Samples were then homogenized 
via FastPrep-24 (MP Biomedicals) with glass beads in the tubes at maximum speed for 
three; 20-second intervals with three 5-minute rests on ice in between. After 
homogenization, samples were aliquoted and stored at -80ºC for later use. 
 
Prion Infections 
Frozen aliquots of 10% normal brain homogenate (NBH) samples from uninfected 
FVB/N mice, as well as RML, 22L, 139A, and mCWD infected mice were used to make 
0.1% dilutions in sterile, 1x PBS. Each BH at 100µL/well was coated onto 96-well TC 
plates in triplicate for each cell of interest and left to incubate inside a TC hood for 1-3-
hours at room temperature. Homogenates were then aspirated off and wells were 
washed twice with 200µL/well of sterile, 1x PBS and aspirated off. Plates were then left 
to dry completely in the TC hood before they were covered in saran wrap and stored at 
4ºC until they were needed. 
 
Wild-type RKM, RK13 mutants, RKV, and RKM7, a highly sensitive, single cell clone 
containing the murine wild-type PrP gene, were trypsinized, counted, and re-suspended 
in complete DMEM with 1µg/mL puromycin and plated at 20,000 cells/100µL/well onto 




left to incubate at 37ºC in 5% CO2 for 4-weeks. Complete cell culture medium with 
puromycin (150µL) was changed every 5-days. 
 
Scrapie Cell Assay 
To elucidate which murine PrP N-glycan substitutions play a significant role in prion 
propagation in prion isolates RML, 22L, 139A, mCWD, and NBH control, the SCA was 
used as a highly immunosensitive means to measure the frequency of PrPSc secreting 
cells at the single-cell level. 
 
Enzyme-linked immunospot (ELISpot) plates (EMD Millipore, Cat. #MSIPN4W50) were 
activated with 70% ethanol and washed three times with 1x PBS, the last wash being 
left on the plates. Cells of interest in a 96-well TC plate were washed once with trypsin, 
aspirated, and fresh trypsin was added. Cells were incubated at 37ºC for 5-20 minutes 
or until cells were detached. Cells were counted and re-suspended in complete DMEM, 
and plated at 20,000cells/100µL/well onto the prepared ELISpot plates containing 1x 
PBS as shown in the NBH examples for each of the corresponding construct locations 
and lysates (Fig. 8A,B). A vacuum was applied to remove media, and plates were 
washed twice with 1x PBS. Plates were placed in a 50ºC oven for 1-hour or until 













Figure 8. ELISpot Plate Layout SCA and analysis layout examples for each of N180 (A) and S/T182 
(B) incubated with NBH (shown), RML, 22L, 139A, or mCWD isolates. Samples were transferred 




Immunodetection of experimentally infected RKM, RK13 mutants, RKV, and RKM7 cells 
on ELISpot plates was performed as previously described (Bian et. al., 2010; Bian et. 
al., 2014) using mAb D13, and scanned with Immunospot S6UNIV equipment (Cellular 
Technology Limited). Spot numbers were then determined by using Immunospot 5.0 
Analysis and 5.1 Counting software (Cellular Technology Limited).  
 
Conformation of Murine PrP N-Glycan Mutations through Genetic Sequencing 
To determine if the mono-1 constructs generated were both accurately and correctly 
inserted into RK13 cells, polymerase chain reactions (PCR) were set up for a few of the 
constructs using primers designed through Integrated DNA Technologies (IDT) to 
amplify either the cytomegalovirus (CMV) promoter in vector pIRESpuro.3 as a positive 
control, or murine PrP encompassing the mutations at sites 180 and 182 using 
pIRESpuro.3.  
 
For each PCR reaction, 12.5 µL of GoTaq master mix (Promega, Cat. #M7122) was 
used in combination with 1.25µL of each forward and reverse primer set at 
concentrations of 10µM each and brought up to 22µL with PCR-grade water. Then, 
500ng/3µL of each DNA template to be tested was added, totaling a 25µL/PCR 
reaction. Tubes were then placed in a Thermocycler (Bio-Rad) detailing a protocol 
specific to the primer design, amplified, and 8µL of the reaction was separated by 
electrophoresis on a 0.8% agarose gel at containing EtBr at 100V for 1-hour for product 





After confirming the appearance of single bands at the correct size (~820bp for murine 
puromycin PrP and ~351bp for CMV), remaining PCR products were purified using a 
QIAquick PCR Purification Kit (Qiagen, Cat. #28104), quantified using a NanoDrop 
2000c Spectrophotometer (Thermo Fisher Scientific), and checked for acceptable salt 
contamination (260/230) and purity (260/280) ratios of ~2.0 and 1.9 respectively 
(Thermo Fisher Scientific, 2009). Sequencing primers were designed to flank the 
mutated region to provide reads on the forward and reverse strands. Samples were 
then sent for sequencing to GENEWIZ, NJ according to the instructions provided. 
Results showed that the construct DNAs tested were the correct mutations at the 
correct site, confirming the successful generation of glycan substitutions at residues 
N180 and S/T182 on murine PrP in RK13 cells. 
 
Results 
Western Blot Analysis 
Western blots have traditionally been used as a reliable readout to detect prion disease 
post-mortem (Hadlow, 1999; Hnasko et. al., 2010; MacGregor, 2001; Pawel, 2004). 
Therefore, we set out analyze immunoreactive bands for both N180 and S/T182 site 
substitutions of the consensus sequence of PrP to confirm mono-1 N-glycan ablation 
and verify PrPC expression including PrP glycoforms. 
 
Data from western blot analysis of substitutions at the N180 site on murine PrP showed 
that all substitutions, with the exception of proline, exhibited immunoreactive bands at 




aglycosylated C1 fragment when membranes were probed with mAb PRC5 (Fig. 9A,C). 
Moreover, these mutations were confirmed to result in the ablation of N-glycan 
attachment at mono-1 of murine PrP as shown by the absence of the di-glycosylated 
glycoform (Fig. 9A). Because it is well known that the properties of P causes a 
disruption in amino acid structure, it can be assumed that P affects N-glycan attachment 
of these mutant cells and can explain the absence of all other bands, except mono-2 
full-length PrP which was detected. Additionally, these same N180 constructs, with the 
exception of P in which there was a complete absence of banding pattern, showed 
bands consistent with aglycosylated full-length PrP and its derivative, aglycosylated C1 
when stained with PRC7 (Fig. 11A,B). These results confirm the successful generation 
of mono-1 PrP mutants and resulting underglycosylation. They also verify the specificity 
of mAb PRC7 for mono-1 because mono-1 is ablated in all of these mutants and no 
band was detected for mono-2 full-length or its derivative, C1. Lastly, detection of all 
PrP glycoforms, excluding the C1 derivative, was shown in all substitutions, excluding 
P, when stained with mAb D13 (Fig. 13A,B). This is explained by the fact that C1 is 
cleaved upstream of the D13 epitope and therefore could not be detected. 
 
Interestingly, results from western blot analysis of substitutions at the murine PrP 
S/T182 site did not yield any immunoreactive bands with either PRC5 or PRC7 (Figs. 
10A,C; 12A,B). It can be hypothesized that these results are due to the fact that the 
discontinuous epitope for PRC7 is a component of mono-1, and the discontinuous 
epitope encompassing PRC5 is just upstream of mono-1 in the globular region of PrP. 




the misfolding of PrPC, which sterically prevents the detection of these mAbs in the 
S/T182 mutations (Fig. 2). Moreover, these data also suggest that S or T constitute part 
of the epitope recognized by PRC5 and PRC7. These results can also be explained by 
the possibility that during processing, PrP in the S/T182 mutants gets flagged by the 
golgi apparatus and gets caught in the cytoplasm of the cell and is unable to be fully-
processed and sent to the cell surface for expression and detection. Furthermore, 
mono-2 full-length bands were recognized by mAb D13, which is located upstream of 
the globular region in these mutant cells (Fig. 2). These results further demonstrate that 
PrP is expressed at some level in the S/T182 mutations but may not be transported to 
the cellular surface. Interestingly, there was also doublet identified in the N mutation 
with the D13 mAb (Fig. 14A,B). This doublet shows mono-2 full-length bands that are 
similar in size to those of the N180 mutants. The sequence of the S/T182N mutant was 
checked to confirm that there was not a downstream cryptic consensus motif. Analysis 
of the amino acid sequence of the mutation shows that the N substitution does not 
result in a cryptic glycosylation site as the downstream amino acid at 184 is K, not the 
S/T that is required for the consensus sequence (Fig. 5).  
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Figure 9. Representative N180 Site Mutation (Mono-1) Western Blots Probed with PRC5 and 
GAPDH N180 site mutations in mo PrP are shown along with controls including freshly infected cells 
expressing WT mo PrP (RKM 1-3), a highly expressive clone expressing WT mo PrP (RKM7), cells 
containing the empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML). 
Samples (50µg total protein) were run twice to confirm bands and probed with mAbs PRC5 at 1:5000 
(A) and (C), and GAPDH at 1:3000 (B) and (D). All samples containing glycan substitutions with the 
exception of proline (P), showed detection of all PrP glycoforms and their derivatives, as predicted. For 
all western blots in this body of work, the immunoreactive bands labeled in (A) as D=diglycosylated 
full-length, M=monoglycosylated (mono-2) full-length, Un=aglycosylated full-length, C1=derivative 
fragments of monoglycosylated and aglycosylated). All samples were evenly loaded as shown by 













Figure 10. Representative S/T182 Site Mutation (Mono-1) Western Blots Probed with PRC5 
and GAPDH ST182 site mutations in mo PrP are shown along with controls including freshly 
infected cells expressing WT mo PrP (RKM 3), a highly expressive clone expressing WT mo PrP 
(RKM7), cells containing the empty vector (RKV), and RKM7 cells chronically infected with RML 
(RKM7/RML). Samples (50µg total protein) were run twice to confirm bands and probed with 
mAbs PRC5 at 1:5000 (A) and (C), and GAPDH at 1:3000 (B) and (D). No samples containing 
glycan substitutions showed detection of any PrP glycoforms or their derivatives. A transfer error 
























Figure 11. Representative N180 Site Mutation (Mono-1) Western Blots Probed with PRC7 N180 
site mutations in mo PrP are shown along with controls including freshly infected cells expressing WT 
mo PrP (RKM 3), a highly expressive clone expressing WT mo PrP (RKM7), cells containing the 
empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML). Samples (50µg total 
protein) were run twice to confirm bands and probed with mAb PRC7 at 1:3000 (A) and (B). All 
samples containing glycan substitutions with the exception of proline (P), showed detection of the 
PRC7-specific glycoform, aglycosylated full-length, and its derivative, C1. Blots were also probed with 















Figure 12. Representative S/T182 Site Mutation (Mono-1) Western Blots Probed with PRC7 
S/T182 site mutations in mo PrP are shown along with controls including freshly infected cells 
expressing WT mo PrP (RKM 3), a highly expressive clone expressing WT mo PrP (RKM7), cells 
containing the empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML). 
Samples (50µg total protein) were run twice to confirm bands and probed with mAb PRC7 at 1:3000 
(A) and (B). No samples containing glycan substitutions showed detection of any PrP glycoforms or 
















Figure 13. Representative N180 Site Mutation (Mono-1) Western Blots Probed with D13 N180 
site mutations in mo PrP are shown along with controls including freshly infected cells expressing WT 
mo PrP (RKM 1-3), a highly expressive clone expressing WT mo PrP (RKM7), cells containing the 
empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML). Samples (50µg total 
protein) were run twice to confirm bands and probed with mAb D13 at 1:5000 (A) and (B). All samples 
containing glycan substitutions with the exception of proline (P), showed detection of all PrP 
glycoforms, excluding the aglycosylated C1 derivative, as predicted, which is cleaved upstream of the 










Scrapie Cell Assay 
The SCA developed previously by Klohn and colleagues has been utilized in our lab 
and modified for detection using newly developed mAbs (Bian et. al., 2010; Bian et. al., 
2014). In this body of work, the SCA was used to determine which murine PrP N-glycan 
Figure 14. Representative S/T182 Site Mutation (Mono-1) Western Blots Probed with D13 S/T182 
site mutations in mo PrP are shown along with controls including freshly infected cells expressing WT 
mo PrP (RKM 3), a highly expressive clone expressing WT mo PrP (RKM7), cells containing the 
empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML). Samples (50µg total 
protein) were run twice to confirm bands and probed with mAb D13 at 1:5000 (A) and (B). All samples 
containing glycan substitutions showed detection of mono-2 full-length, with the exception of 
Asparagine (N), which shows mono-1 and mono-2 full-length due to the substitution of N for S/T. This 
substitution does not create a cryptic glycosylation site, as the downstream amino acid at 184 in the 
consensus sequence is lysine (K) not S or T. Blots were also probed with GAPDH to establish evenly 




substitutions play a significant role in prion propagation in RML, 22L, 139A, and mCWD 
prion isolates through single-cell PrPSc secretion. 
 
Results from mutations made at sites N180 and S/T182 in murine PrP that were 
infected, plated, and analyzed through mAb D13 detection using SCA showed 
significant prion replication (P ≤ 0.001) to near murine PrP control levels (RKM 1-3) as 
compared with RKV in the N180T mutant infected with RML, and in four 22L-treated 
N180 substitutions: N180D, N180E, N180K, and N180R (Tables 1-2; Fig. 15) when 
analyzed through one-way ANOVA with Tukey’s multiple comparison test. These data 
suggest that N180 site mutations T, D, E, K, and R play a role in murine conversion of 
PrPC to PrPSc. Additionally, these findings combined with preliminary data by Kang and 
colleagues further emphasize the importance of looking at individual amino acid 
changes at each of the two N-linked glycan sites on PrP to study their effects on 
propagation prior to further investigation in murine models. 
 
The properties of the N180 substitutions that allowed prion propagation to occur are 
summarized in Table 5. The only commonality between these mutations is the physical 
property of polarity (Table 5). As glycosylation does not encompass everything 
influencing PrP conversion, it is also necessary to further examine the effects of polarity 
in prion disease highlighting the differences between polar mutations that allowed prion 
propagation and those that did not.  
 
Alternatively, data show that there was a complete absence of prion propagation in all 




propagation for mutations at the S/T182 site by SCA using mAb D13, yet one mono-2 
full-length band is detected by immunoblotting because of the possibility that PrP is 
expressed at some level in the S/T182 mutations but may not be transported to the 
cellular surface to be able to become infected by prions. In other words, the proper 
cellular expression of PrP that is required for the conversion of PrPC to PrPSc in the 
S/T182 mutants is not available, yet a partially processed form of PrP within the 
cytoplasm of the cell was available to be extracted and analyzed through western blot 
analysis as PrPC. Moreover, after infection and subsequent PrPC removal in the SCA, 
there was no protease resistant core available for detection with D13 in any S/T182 
substitution.  
 
Table 1. Summary of PrP
Sc




Summary of individual cell spot counts per well representing PrP
Sc
 production in prion isolates RML, 
22L, 139A, and mCWD and NBH for N180 mutation substitutions. Each mutation and control was 
infected in triplicate and plated onto ELISpot plates 4-weeks after infection. Prion replication was 
detected to near mo PrP control levels (RKM 1-3) in one mutant infected with RML (T), and in four 




Table 2. Averages of PrP
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Averages of individual cell spot counts representing PrP
Sc
 production in prion isolates calculated from 












Figure 15. Scrapie Cell Assay N180 PrP
Sc
 production in different murine prion RML (purple), 22L 
(red), mCWD (green), and 139A (blue), as well as control NBH (orange) for the N180 site 
substitutions. Each mutation was infected and plated along with controls; freshly infected cells 
expressing WT mo PrP (RKM 1-3), a highly expressive clone expressing WT mo PrP (RKM7), cells 
containing the empty vector (RKV), and RKM7 cells chronically infected with RML (RKM7/RML), onto 
ELISpot plates 4-weeks after infection. Detection of infected cells was done using mAb D13 at 1:600. 
Prion replication was detected to near mo PrP control levels (RKM 1-3) in one mutant infected with 




Table 3. Summary of PrP
Sc
 production in different murine prion isolates for S/T182 site substitutions  
 
 
Table 4. Average of PrP
Sc




Summary of individual cell spot counts per well representing PrP
Sc
 production in prion isolates RML, 
22L, 139A, and mCWD and NBH for S/T182 mutation substitutions. Each mutation and control was 
infected in triplicate and plated onto ELISpot plates 4-weeks after infection. Prion replication was not 
detected to near control mo PrP levels (RKM 3) in any prion isolate tested. 
Averages of individual cell spot counts representing PrP
Sc
 production in prion isolates calculated from 










Figure 16. Scrapie Cell Assay S/T182 PrP
Sc
 production in different murine prion isolates 
RML (purple), 22L (red), mCWD (green), and 139A (blue), as well as control NBH (orange) 
for the S/T182 site substitutions. Each mutation was infected and plated along with controls; 
freshly infected cells expressing WT mo PrP (RKM 3), a highly expressive clone expressing 
WT mo PrP (RKM7), cells containing the empty vector (RKV), and RKM7 cells chronically 
infected with RML (RKM7/RML), onto ELISpot plates 4-weeks after infection. Detection of 
infected cells was done using mAb D13 at 1:600. Prion replication was not detected to near 









Finally, in terms of the outcomes of PCR amplification and subsequent DNA sequencing 
of three constructs, S/T182W (tryptophan), S/T182Y (tyrosine), and N180D (aspartic 
acid), the successful generation of stable RK13 cells expressing mutations at either 
N180 or S/T182 on murine PrP was confirmed (Figs. 17; 18). All samples showed 
positive bands for murine puro PrP (~820bp) and CMV (~351bp), indicating the 
presence of these sequences in the DNA of the stably transfected cells. Additionally, 
DNA sequencing results confirmed the correct mutation for each construct in murine 
Summary of N180 substitutions that showed a significant increase (P ≤ 0.001) in prion replication to 
near WT levels (RKM 1-3) in one mutant infected with RML (T), and in four 22L treated mutants 
(D,E,K, and R). Bolded codons were used in the generation of these constructs. The one consistent 




PrP. One thing of importance to note is that the N180D construct is one of four that 
showed significant prion propagation in 22L while S/T182W and Y are constructs that 
did not allow prion proliferation. Therefore, the lack of prion replication in the S/T182 
mutations cannot be explained by the absence of the correct inserts incorporated into 









Figure 17. Murine PrP and CMV PCR Agarose gel of amplified 500ng of DNA template from three 
representative N180 and S/T182 site mutations. Mo puro PrP (red box), CMV promoter (blue box). 
Two representative S/T182 substitutions negative for prion propagation and one N180 mutation shown 
to replicate prions were chosen for PCR amplification and genetic sequencing to confirm stable 
transfections. All samples showed positive bands for mo puro PrP (~820bp) and CMV (~351bp), 







In recent years, more work has been implemented into improving our understanding of 
the role of glycosylation in prion disease (Cancellotti et. al., 2005; Cancellotti et. al., 
2010; DeArmond et. al., 1997; Tuzi et. al., 2008). Preliminary data by Kang and 
colleagues combined with the results in this body of work collectively show the first 
evidence of the effects of underglycosylation on prion prorogation by treating each N-
glycan attachment site on PrP individually.  
 
In this body of work, individual amino acid substitutions were made at two points on the 
mono-1 glycan attachment encompassing the consensus sequence NXS/T. Removal of 
this glycosylation event permitted the study of the role of underglycosylation in prion 
disease. This approach to the current study was largely based on unpublished data 
obtained by Kang and colleagues in which the mono-2 N-glycan site on murine PrP was 
individually mutated at either N196 or T198 to each of the remaining 19 amino acids. 
Afterward, cells were treated with NBH, and prion isolates RML, 22L, 139A, and mCWD 
and analyzed for prion propagation. 
Figure 18. Murine PrP DNA Sequencing Analysis of one representative mutant PrP DNA shows the 
confirmation of the correct PrP sequence for the S/T182W mutation (arrow) as compared with mo WT 




Ablation of the Mono-1 N-Glycan Attachment on PrP and PrPC expression 
Western blots have traditionally been used as a reliable readout to detect prion disease 
(Hadlow, 1999; Hnasko et. al., 2010; MacGregor, 2001; Pawel, 2004). In this body of 
work, we analyzed immunoreactive bands for N-glycan mutations made at N180 and 
S/T182 of murine PrP. PrPC expression was visualized using mAbs PRC5, PRC7, and 
D13. Results confirmed the ablation of the mono-1 N-glycan attachment at both sites. 
 
All N180 site mutations exhibited the expected PrP glycoforms and their derivatives with 
the exception of P when probed with mAbs PRC5, PRC7, and D13. It has been 
demonstrated that P cannot be located in the second motif of the consensus sequence, 
NXS/T. This is largely due to the fact that P is bound in a loop that forms a 180-degree 
turn. Therefore, it can be assumed that the substitution at N180P acts in a similar way 
(Marshall, 1972). Additionally, N180 glycan results confirm that the lack of one glycan 
attachment in the mutants does not de-stabilize the entire protein structure to the extent 
where they acquire PrPSc like characteristics, such as a protease resistant core 
(Lehmann and Harris, 1997; Korth et. al., 2000; Winklhofer et.al., 2003). However, it 
was shown that PrP with alterations to N-glycans exhibit evidence of PrPSc like 
characteristics, like insolubility in detergents, while maintaining sensitivity to protease 
treatment (Neuendorf et. al., 2004). 
 
Interestingly, results from western blot analysis of substitutions made at S/T182 on 
murine PrP resulted in the complete absence of immunodetection with conformationally 




unstructured region consisting of a linear epitope, one lower immunoreactive band for 
mono-2 full-length was detected in all mutations with the exception of S/T182N, in which 
a doublet formed resembling the banding pattern of the N180 substitutions stained with 
D13. Overall, these results suggest that PrP is expressed to some level in the S/T182 
mutations, but may not be transported to the cellular surface for detection or prion 
conversion. Moreover, the primary sequence for the N-glycan substitution S/T182N was 
checked at amino acid 184 to confirm that a new cryptic glycosylation site was not 
initiated.  
 
Ablation of the Mono-1 N-Glycan Attachment on PrP and Prion Propagation 
Prior attempts have been made to address the role of post-translational modifications in 
prion propagation. However, these studies fail to recognize prion biology in its entirety. 
Any mutation at the first or the third amino acid of the glycan consensus sequence on 
PrP results in the ablation of glycan attachment. Therefore, it is necessary to study point 
mutation changes at each of the two N-linked glycan sites on PrP and analyze their 
effects on propagation prior to investigation at the level of the organism. 
 
Earlier investigations include in-vivo PrP glycosylation studies using knock-in or gene 
replacement approach to partly or fully ablate glycan attachments on PrP in mice that 
substitute T for N. These studies have reported little to no prion propagation (Cancellotti 
et. al., 2005; Cancellotti et. al., 2010). Importantly, these substitutions have been 
described to affect PrP processing through the secretory pathway, and make it difficult 




aglycosylation, potentially low concentrations of PrPC on the cell surface, or improper 
folding of the tertiary structure (Capellari at. al., 2000; Korth et. al., 2000).  
 
Other research include studies completed by DeArmond and colleagues in which 
genetically modified mice were generated with an A replacing the T at each N-glycan 
site. Results indicated that prion transmission to these mice was strain-selective and 
less efficient than in mice expressing normal PrP glycosylation (DeArmond et. al., 1997; 
Tuzi et. al., 2008). Therefore, it is uncertain whether or not these discrepancies might be 
related to the varying amino acid substitutions used to obliterate PrP glycosylation.  
 
In the present study, the SCA was chosen as the main readout for prion propagation 
and used prion strains RML, 22L, 139A mCWD, and NBH control. This assay was 
selected based off of its highly immune-sensitive properties to measure the number of 
PrPSc secreting cells post-infection. Immunodetection of experimentally infected RKM, 
RKV, RKM7, and RK13 glycan point mutations were performed using mAb D13 as 
described formerly (Bian et. al., 2010; Bian et. al., 2014). Data obtained from mutations 
made at N180 and S/T182 encompassing the mono-1 glycan site showed significant 
prion propagation (P ≤ 0.001) equivalent to RKM control levels after infection with RML 
or 22L in N180T, N180D, N180E, N180K, and N180R. These data suggest that N180 
site mutations T, D, E, K, and R play a role in murine conversion of PrPC to PrPSc. 
Alternatively, a complete absence of prion replication was found in all modifications 




membrane-bound PrPC that is necessary for conversion likely caused by a disruption in 
cellular processing and trafficking. 
 
One potential flaw in the results of the SCA of this study is that only the RKM7 WT 
control samples infected with prion strain 22L exhibited PrPSc positive cell numbers 
comparable to the chronically infected control, RKM7/RML. This outcome makes the 
data inconclusive without additional replicates. It is possible that these results may be 
due to either a technical error in the assay, or to a BH titer difference that was not 
accounted for. Brain weight does not necessarily correspond with the amount of PrPSc 
in a sample. Therefore, it can be assumed that there was likely some variability in PrPSc 
expression between BHs used in this study. To account for this, replicate studies should 
be performed using several isolates for each strain and a consistent trend observed 
before results can be considered conclusive.  
 
In contrast to the aforementioned study performed by Cancellotti and colleagues, our 
N180T mutation at mono-1 resulted in the detection of significant levels of PrPSc by SCA 
after infection with RML to near RKM levels (Cancellotti et. al., 2005; Cancellotti et. al., 
2010). Furthermore, preliminary data by Kang and colleagues demonstrated that the 
N196T mutation at mono-2 had an increase in the levels of PrPSc by SCA when infected 
with RML, 22L, 193A, and mCWD. Therefore, the substitution of T for N at either glycan 
site on PrP may play a role in prion replication. Alternatively, in the present study, there 
was a complete absence of prion propagation in all substitutions made at the third 




139A, and mCWD. These results may bring insight into why lower replication efficiency 
was seen in genetically modified mice consisting of an A rather than a T at each glycan 
site on PrP as seen in former investigations by DeArmond and colleagues (DeArmond 
et. al., 1997).  
 
Ablation of the Mono-1 N-Glycan Attachment on PrP and Trafficking to the Cell 
Membrane 
As previously thought, complete sugar attachment is not required to make a 
glycoprotein functional and stable (Heleius and Aebi, 2001; Lowe and Marth, 2003). In 
2005, it was shown by Cancellotti and colleagues that the presence of a single sugar 
chain is adequate enough for the successful trafficking of PrP to the cell membrane 
(Cancellotti et. al., 2005). They also reported that while glycans appear to control the 
cellular location of PrP, the presence of sugars does not considerably change its 
biology. In the present study, we addressed the same question using our point mutation 
in-vitro model of N-glycosylation by altering each of the sugar attachments on PrP to 
each of the remaining amino acids and treating them individually.  
 
In the current study, mutations were made at mono-1 at two locations and contain only 
one N-glycan attachment at mono-2. These alterations do not create an immature 
glycoprotein unable to be expressed at the cell surface as suggested (Hershko and 
Ciechanover, 1998; Neuendorf et. al., 2004; Petersen et. al., 1996). These inferences 
are supported by successful PrPC immunodetection in the N196, T198, and N180 site 




Moreover, after infection, mutations N180T, N180D, N180E, N180K, N196K, and 
N180R resulted in significant and quantifiable PrPSc expression that is comparable to 
RKM levels by SCA. This further suggests that these mutations were processed 
correctly in the cell despite the lack of one glycan attachment. 
 
However, the substitutions made at the S/T182 site are an exception to these 
conclusions. In general, the inability for these mutations to express immunoreactive 
bands using conformationally dependent mAbs that are consistent with expected PrP 
glycoforms indicates that they were not fully processed and anchored at the cell 
surface. One explanation for this outcome is that the because mono-1 is located directly 
in α-helix 2, the S/T182 point mutations disrupt the three-dimensional structures of PrP 
to the extent that the un-manipulated mono-2 N-glycan attachment is unable to become 
fully glycosylated as shown by immunoreactive bands for the N180 mutations. This 
outcome may be due to possible steric hindrance of the folding of the protein. As a 
consequence, all S/T182 mutations, with the exception of S/T182N, may have resulted 
in a species of PrP that does not have a fully glycosylated glycan at mono-2 as 
demonstrated by the difference in band width when comparing D13 blots between the 
S/T182 and N180 site mutants. Therefore, the point mutations made at S/T182 may 
represent more of an aglycosylated species of PrP. This theory is supported by 
research that shows aglycosylated PrP gets trapped intracellularly during processing 
(DeArmond et. al., 1997; Lehmann and Harris, 1997; Harris, 2003; Rogers et. al., 1990). 
Alternatively, Korth, Neuendorf, and colleagues were able to detect aglycosylated PrP 




suggest that the modification of a single amino acid, rather than the complete absence 
of a sugar attachment can influence cellular localization of PrP (Korth et. al., 2000; 
Neuendorf et. al., 2004).  
 
Ablation of the Mono-1 N-Glycan Attachment on PrP and Secondary and Tertiary 
Structures 
Of the 20 amino acids that occur naturally, 6 are considered to be clearly polar. These 
include negatively charged D and E, positively charged R, and K, as well as uncharged 
N and Q (Betts and Russell, 2003). Other slightly polar or indifferent amino acids 
include H, A, Y, T, S, P and G. The properties of the amino acid are due to the side-
chain group (R-group) which is important when it comes to the primary structure of a 
protein. These properties drive the folding and intrarmolecular bonding of the linear 
amino acid chain that determines the protein’s overall shape. All polar amino acids have 
a hydrophilic side-chain when in an aqueous environment and can therefore make 
hydrogen bonds with other suitable groups. For this reason, these amino acids are 
found exposed on the surface of a protein (Betts and Russell, 2003). 
 
Due to the nature of the weak interactions controlling the three dimensional structure, 
proteins are very sensitive molecules. The native state can be disrupted by a number of 
external stress factors including pH or the removal of water (Betts and Russell, 2003) 
Moreover, any mutation that causes an amino acid substitution can have a large 
influence on protein structure and subsequent protein function. In this body of work, only 




prion propagation with the exception of one slightly polar replacement, N180T through 
detection by SCA. The chemistry of amino acid side chains is critical to protein structure 
because they bond with one another and hold the protein in a certain conformation. 
Regardless, the alterations of the primary sequence on murine PrP made at mono-1 
that allow prion replication share the property of polarity with the native amino acid N at 
residue 180 in PrP. This common characteristic could mean that a polar amino acid at 
residue 180 of mono-1 is required for the successful conversion of PrPC to PrPSc by 
maintaining the α-helix structure. This finding is novel because mono-1 resides within 
the second helix of PrP and any change in primary structure can greatly impact 
subsequent protein folding and interactions.  
 
It is important to point out that not every polar mutation made in this study supported 
prion propagation. Furthermore there was no consistency observed between the charge 
of the side-chain and prion conversion. These realizations result in further questions 
regarding point mutation changes at the N-glycan consensus sequence and their 
involvement in prion propagation. It is no surprise then that generating and assessing 
individual amino acid mutations for each of the N-glycan sites on PrP was both time 
consuming and costly. There are other ways in which investigators could strategically 
manipulate the consensus sequence and ask a more specific question. However, this 
body of work lays important groundwork that provides an overview for other researchers 
to base new questions on in future investigations. 




It remains uncertain whether or not an intermediate species of PrP is required for 
conversion of PrPC to PrPSc. Solving the structure of PrPC has provided one part of the 
equation, however our lack of knowledge of the tertiary structure of PrPSc remains a 
clear deficiency. An emphasis needs to continue on studying the post-translational 
differences between PrPC and PrPSc in order to fully understand the prion hypothesis 
and PrPSc. Deciphering the structure of PrPSc will then identify how PrPC is altered and 
lead to a better understanding of the mechanism of conversion and succeeding 












This body of work completes the initial series of studies started by Kang and colleagues 
to decipher the role of aglycosylation in prion disease through amino acid substitutions 
at each of the two N-glycan sites on murine PrP and subsequent prion conversion using 
four prion strain isolates (RML, 22L, 139A and mCWD).  
 
Collectively, these studies show the first evidence of the effects of aglycosylation on 
prion propagation by treating each of the glycan attachment sites on PrP individually. 
These preliminary findings establish the importance of post-translational differences 
between PrPC and PrPSc which constitute an essential, unresolved aspect of the prion 
hypothesis several decades after it was first proposed. The core hypothesis of this body 
of work, that PrPSc is preferentially generated during prion propagation, in addition to the 
specific aims addressed which attempt to investigate the relationship of individual 
mono-1 mutations on murine PrP through PrPC expression and subsequent propagation 
using four prion isolates, represent both a novel and significant development in 
understanding the mechanism by which prions replicate.  
 
 
Future Directions  
Processing of PrP Mutants 
Once preliminary results from this body of work are confirmed through additional 




processing of these N-linked glycan mutations in the cell prior to infection. These 
experiments will include assays in which the trafficking, distribution, and cellular 
membrane occupancy of the individually mutated prion proteins can be studied. While 
the proper folding of PrP in combination with the ability to support prion propagation is 
consistent with correct protein processing and cellular distribution, it is important to 
confirm, especially in S/T182 mutants in which prion propagation was entirely un-
detected, that the mutated proteins at both mono-1 and mono-2 were able to reach the 
cellular membrane successfully. These studies could be executed by using genetically 
encoded fluorophores, such as super ecliptic pHluorin (SEP), a PH-sensitive derivative 
of green fluorescent protein (GFP) commonly used in live cell imaging (Ashby et. al., 
2004; Sankaranarayanan et. al., 2000) In these experiments, SEP would be used as a 
tag to visualize PrP within living cells in real-time. These studies will allow us to 
determine whether or not the S/T182 site mutations specifically are being processed 
correctly or getting stuck in the cell resulting in the inability for them to be expressed at 
the cell surface. Alternatively, immunocytochemical prion detection using discriminatory 
and non-discriminatory mAbs followed by flow cytometry would be another means to 




Following the confirmation of proper processing within the cell, biochemical analysis of 
cells containing each mutated PrP will be performed. In these experiments, fractionation 




and macromolecules. Fractionation would allow us to reduce the size of the protein pool 
to be analyzed and enable us to focus on proteins located within certain cellular 
compartments. This would enable us to focus specifically on PrP for analysis and 
interpretation so we can characterize the PrP mutations with respect to mono-1 or 
mono-2.  
 
Other Future Studies 
Coupled with NMR or x-ray crystallography, these techniques would allow us to obtain 
functional and structural information regarding these N-glycan substitutions in PrP. Our 
goal would be to introduce mutations at both the mono-1 and mono-2 sites on PrP into 
RK13 cells that consist solely of the formation of aglycosylated murine PrP with the 
capability for prion conversion. These cells would undergo infection using several prion 
isolates and control NBH. Thereafter, the same analyses would be performed on these 
double mutants with potential to move forward to in-vivo mouse models for further 
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